Early Development Team Leader

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. On August 8 th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say . For more information, please visit www.arvinas.com . Position Summary Arvinas is seeking a highly motivated and experienced Asset Team Leader to lead cross-functional teams that are accountable, in partnership with the functional leaders on the Asset Team, for the strategy and seamless execution of early oncology development programs. The successful candidate will work to recommend and drive the strategy of early oncology assets and execution against planned timelines. The Asset Team Leader will lead a cross-functional team including clinical research, clinical operations, regulatory affairs, clinical pharmacology, translational/companion diagnostics, CMC, non-clinical, medical affairs and New Product Planning to deliver against the program strategy. The successful candidate will have experience in early phase development of oncology or related programs. This role will report to the SVP, Asset Strategy and Team Leadership and can be remote, hybrid, or located at our headquarters in New Haven, CT. Principal Responsibilities Key responsibilities of this role include, but are not limited to: Lead cross-functional oncology asset teams and act as main point of contact and program representative to executive management Negotiate with and influence key internal and external stakeholders Drive generation and execution of the program strategy and Integrated Development Plans with a multidisciplinary matrixed team